2018
DOI: 10.1097/pai.0000000000000435
|View full text |Cite
|
Sign up to set email alerts
|

Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification

Abstract: Little is known about the aminopeptidase CD13 in renal neoplasia according to the new 2016 World Health Organization renal tumor classification. We selected 175 cases, including 79 clear cell, 31 papillary, 24 chromophobe, 8 clear cell papillary renal cell carcinomas (RCCs), 21 oncoytomas, and 12 microphthalmia transcription factor family translocation RCCs: 4 t(6;11)/transcription factor EB (TFEB), 7 t(Xp11) with 2 cystic variants and 1 t(X;17). GATA binding protein 3 (GATA-3) was inserted as control. Express… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 30 publications
0
4
0
Order By: Relevance
“…Indeed, there is a very active research on tumor stratification based on CD13 expression, and there are many reports in the literature indicating that CD13 expression is an unfavorable prognosis factor in a variety of cancers. Those tumors include pancreas [10] and colon cancers [11], non-small cell lung cancer [12,13], malignant pleural mesothelioma [14], hepatoblastoma [15], hepatocellular carcinoma [35], clear cell papillary renal cell carcinoma [36], scirrhous gastric cancer [37], lymphoplasmatic lymphoma [38], and soft tissue sarcoma [16]. Some of these tumors are rare and/or have poor prognosis, and new therapeutic approaches are urgently needed to increase patient's survival.…”
Section: Discussionmentioning
confidence: 99%
“…Indeed, there is a very active research on tumor stratification based on CD13 expression, and there are many reports in the literature indicating that CD13 expression is an unfavorable prognosis factor in a variety of cancers. Those tumors include pancreas [10] and colon cancers [11], non-small cell lung cancer [12,13], malignant pleural mesothelioma [14], hepatoblastoma [15], hepatocellular carcinoma [35], clear cell papillary renal cell carcinoma [36], scirrhous gastric cancer [37], lymphoplasmatic lymphoma [38], and soft tissue sarcoma [16]. Some of these tumors are rare and/or have poor prognosis, and new therapeutic approaches are urgently needed to increase patient's survival.…”
Section: Discussionmentioning
confidence: 99%
“…The labelling for CD10 is usually negative in solid areas, however, cyst lining areas could sometimes display minor focal labelling [ 14 ]. The positive staining for high molecular weight cytokeratin and GATA3 may imply a distal nephron phenotype, in spite of morphological similarity to clear cell renal cell carcinoma [ 23 , 33 ]. Finally, compared to renal cell carcinoma with smooth muscle or leiomyomatous stroma, the labelling for smooth muscle markers, including desmin or caldesmon, can be only poorly visible in ccpRCC pseudocapsule or even less in the stroma [ 34 ].…”
Section: Immunohistochemistrymentioning
confidence: 99%
“…In addition, immunohistochemical staining for p63 has been shown to be useful for distinguishing mucoepidermoid carcinoma from some clear cell tumors [29], and Cluster of Differentiation (CD) 10 expression in RCCs are useful as a marker in the differential diagnosis of several tumors. Moreover, CD13 and GATA binding protein 3 (GATA-3) immunostains may serve as a diagnostic aid in differentiating subtypes of RCC [30].…”
Section: Immunohistochemical Stains For Diagnosismentioning
confidence: 99%